Navigating the procurement of research-grade peptides requires a detailed understanding of the factors driving synthesis expenses, analytical verification costs, and structural purity. KPV (Lys-Pro-Val) is a tripeptide derived from the C-terminal sequence of alpha-melanocyte-stimulating hormone (α-MSH), extensively studied for its potential to modulate inflammatory cascades in preclinical models. This guide provides a definitive analysis of KPV cost parameters, quality verification benchmarks, and handling protocols for institutional researchers.
Navigating the procurement of research-grade peptides requires a detailed understanding of the factors driving synthesis expenses, analytical verification costs, and structural purity. KPV (Lys-Pro-Val) is a tripeptide derived from the C-terminal sequence of alpha-melanocyte-stimulating hormone (α-MSH), extensively studied for its potential to modulate inflammatory cascades in preclinical models. This guide provides a definitive analysis of KPV cost parameters, quality verification benchmarks, and handling protocols for institutional researchers.
Research-grade KPV cost generally ranges between $35 and $70 for standard laboratory quantities (typically 5 mg to 10 mg lyophilizate per vial), depending on verified purity levels, salt form formulation, and the rigor of analytical testing. Lower price points often reflect raw unverified batches, whereas analytical-grade KPV includes comprehensive lot-specific documentation.
When budgeting for laboratory investigations, researchers must weigh raw unit cost against potential trial artifacts caused by residual trifluoroacetic acid (TFA), organic solvents, or heavy metal contaminants. Sourcing KPV verified via reverse-phase high-performance liquid chromatography (RP-HPLC) and liquid chromatography-mass spectrometry (LC-MS) ensures that experimental outcomes are directly attributable to the peptide sequence rather than batch impurities.
KPV is a tripeptide consisting of the amino acid sequence Lysine-Proline-Valine (Lys-Pro-Val). It corresponds to the C-terminal sequence (residues 11–13) of the naturally occurring peptide hormone α-MSH. Despite lacking the full melanocortin receptor-binding sequence found in larger α-MSH analogs, preclinical studies suggest that KPV retains significant anti-inflammatory signaling capability without inducing melanogenesis.
In vitro assays indicate that KPV exerts its primary biological action through the inhibition of nuclear factor kappa B (NF-κB) nuclear translocation. NF-κB serves as a master transcription factor regulating the expression of pro-inflammatory cytokines, including TNF-α, IL-1β, and IL-6. By preventing the translocation of the p65 subunit of NF-κB into the nucleus, KPV downregulates cytokine production in epithelial and immune cell lines.
Furthermore, researchers exploring research-peptides/anti-inflammatory-peptides investigate KPV for its interaction with PepT1 (peptide transporter 1), an intestinal transporter overexpressed during mucosal inflammation. Preclinical models suggest that PepT1-mediated cellular uptake of KPV allows the tripeptide to directly attenuate intracellular inflammatory signaling inside colonic epithelial cells.
Although KPV is a short tripeptide, several technical factors dictate the final manufacturing and retail cost of high-grade research material. Solid-phase peptide synthesis (SPPS) for tripeptides requires meticulous control over coupling efficiencies and racemization prevention. The choice between Fmoc and Boc chemistry, solvent consumption, and resin clearing steps all contribute to baseline production costs.
Post-synthesis purification is the primary differentiator in KPV cost. Standard crude preparations yield variable purity levels (often between 70% and 85%), which are unsuitable for rigorous quantitative research. Achieving high-purity standards (≥98%) requires multiple preparative RP-HPLC passes, which increases solvent utilization, reduces net mass yield, and drives up overall production overhead.
Salt exchange processes also influence final pricing. Standard SPPS cleavage yields KPV as a TFA salt. Because TFA can exert cytotoxic effects on cell cultures during in vitro studies, converting the compound to an acetate or hydrochloride salt form requires additional processing steps. Institutional buyers inspecting the all-peptides catalog should account for salt form specifications when evaluating cost structures.
To ensure experimental validity, researchers should look beyond initial purchase price and demand complete transparency regarding product analytical verification. A reliable Certificate of Analysis (COA) must accompany each specific batch of KPV 5mg, confirming identity, purity, and safety parameters through independent laboratory testing.
Essential analytical documentation includes an RP-HPLC chromatogram showing a clear single peak representing the primary peptide sequence, with total integration demonstrating ≥98% purity. Additionally, electrospray ionization mass spectrometry (ESI-MS) or LC-MS data must verify the correct molecular weight of KPV (341.4 g/mol for the free base).
At PX1 Research, every batch undergoes third-party verification in ISO 17025 accredited facilities located in the United States. We provide full lot-specific analytical reports including endotoxin testing (<0.01 EU/mg limit) to ensure that in vitro and animal models remain free from bacterial lipopolysaccharide (LPS) artifacts.
The scientific literature regarding KPV focuses heavily on gastrointestinal pathophysiology and mucosal barrier restoration. Rodent models of dextran sulfate sodium (DSS)-induced colitis demonstrate that oral or systemic administration of KPV significantly reduces macroscopic inflammation, histological tissue damage, and myeloperoxidase activity within intestinal mucosal tissue.
In vitro models utilizing Caco-2 cell monolayers show that KPV treatment preserves epithelial tight junction integrity during challenges with inflammatory stimuli. By stabilizing tight junction proteins such as ZO-1 and occludin, KPV helps prevent hyperpermeability associated with mucosal inflammation. Researchers evaluating intestinal barrier kinetics can review detailed study parameters in the PX1 research library.
Additionally, preliminary animal research suggests potential antimycotic properties. In vitro studies demonstrate that KPV inhibits the hyphal transition and growth of *Candida albicans*, suggesting a dual mechanism of action that combines direct immune modulation with local microbial defense mechanisms.
When designing preclinical protocols for tissue repair and inflammation modulation, researchers often evaluate KPV alongside related signaling peptides. Understanding the functional differences between these compounds helps justify allocation of laboratory research budgets.
Unlike BPC-157, which is a 15-amino acid pentadecapeptide focused primarily on angiogenic pathways, nitric oxide modulation, and soft tissue repair, KPV acts predominantly as an intracellular NF-κB suppressor and mucosal immunomodulator. Meanwhile, research compounds such as Larazotide Acetate specifically target tight junction assembly regulation (zonulin antagonism) without the direct intracellular anti-inflammatory signaling characteristic of KPV. For broader immune system modulation studies, researchers may also contrast KPV with antimicrobial peptides like LL-37.
Proper handling and storage of lyophilized KPV are critical to maintaining structural integrity and preventing degradation, thereby protecting laboratory investments. Lyophilized KPV powder should be stored at -20°C upon receipt, protected from light and moisture exposure.
Reconstitution protocols require dissolving the lyophilized cake in sterile, deionized water or phosphate-buffered saline (PBS, pH 7.4). For long-term liquid storage, reconstituting in sterile bacteriostatic water containing 0.9% benzyl alcohol prevents microbial growth. Once reconstituted, solution aliquots should be frozen at -20°C or -80°C to avoid repeated freeze-thaw cycles, which can cause peptide bond cleavage.
Because KPV is a short tripeptide, it exhibits high aqueous solubility. However, researchers conducting in vitro cell culture studies should ensure that stock solutions are prepared using endotoxin-free sterile buffers to avoid confounding cellular activation pathways.
For academic institutions, biotechnology firms, and high-throughput screening projects, procurement costs can be optimized by transitioning from single-vial purchases to bulk tier agreements. Sourcing larger batch quantities reduces per-milligram costs while maintaining standardized lot uniformity across extended research timelines.
PX1 Research supports institutional procurement through our wholesale program, offering custom synthesis scales, specialized salt options (such as acetate conversion), and dedicated batch reservation. Bulk orders undergo identical analytical verification—including full HPLC, LC-MS, and endotoxin testing—ensuring that scale does not compromise analytical accuracy.
The overall cost structure of research peptides is heavily influenced by manufacturing location and supply chain logistics. Overseas suppliers may offer lower upfront prices, but often present risks such as inconsistent purity, lack of lot-level traceability, high endotoxin levels, and extended transit times that compromise temperature-sensitive peptides.
PX1 Research mitigates these risks by maintaining domestic USA synthesis under strict GMP-compliant guidelines. Operating dual fulfillment centers in California and Arizona allows us to provide same-day shipping (Monday through Friday), ensuring rapid transit times and minimizing exposure to extreme environmental conditions during delivery.
What is the average cost of research-grade KPV?
Research-grade KPV typically costs between $35 and $70 per 5 mg to 10 mg vial. Prices vary based on analytical purity verification (≥98%), salt form conversion (acetate vs. TFA), and full lot-specific COA testing including LC-MS and endotoxin screening.
Why is third-party HPLC and LC-MS testing important for KPV cost evaluation?
Third-party RP-HPLC and LC-MS testing confirms the precise chemical identity and sequence purity of KPV. Without independent verification, unpurified peptides may contain residual synthesis solvents, incomplete sequences, or TFA, which can introduce artifacts in preclinical research models.
What is the sequence and molecular weight of KPV?
KPV is a tripeptide with the sequence Lysine-Proline-Valine (Lys-Pro-Val). Its molecular formula is C16H30N4O4, with a theoretical molecular weight of 341.42 g/mol in its free base form.
What preclinical models is KPV used for?
KPV is primarily researched in preclinical models of inflammatory bowel disease (IBD), mucosal inflammation, ulcerative colitis, skin inflammation, and tight junction integrity assays in cell culture lines such as Caco-2.
How should lyophilized KPV be stored in the laboratory?
Lyophilized KPV powder should be stored desiccated at -20°C or -80°C for long-term stability. Avoid exposure to light, heat, and moisture to prevent chemical degradation.
What is the recommended diluent for KPV reconstitution?
For in vitro assays, KPV is typically reconstituted in sterile PBS or endotoxin-free water. For extended liquid stability in laboratory settings, sterile bacteriostatic water (0.9% benzyl alcohol) is commonly utilized.
How does KPV differ from full-length α-MSH?
Alpha-MSH is a 13-amino acid peptide that activates melanocortin receptors (MC1R-MC5R), causing both anti-inflammatory and pigmentary (melanogenic) effects. KPV represents only the C-terminal tripeptide fragment; it inhibits NF-κB signaling without stimulating melanogenesis.
What are the advantages of sourcing KPV from US-based facilities?
Sourcing KPV domestically from US facilities ensures strict adherence to quality control standards, transparent lot tracking, verified endotoxin limits, and rapid transit via temperature-controlled shipping methods from local warehouses.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.